ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR131/071/SRR13180571/SRR13180571_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR131/077/SRR13180577/SRR13180577_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR131/069/SRR13180569/SRR13180569_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR131/075/SRR13180575/SRR13180575_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR131/071/SRR13180571/SRR13180571_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR131/076/SRR13180576/SRR13180576_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR131/077/SRR13180577/SRR13180577_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR131/095/SRR13198895/SRR13198895_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR131/074/SRR13180574/SRR13180574_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR131/070/SRR13180570/SRR13180570_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR131/074/SRR13180574/SRR13180574_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR131/076/SRR13180576/SRR13180576_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR131/072/SRR13180572/SRR13180572_1.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR131/095/SRR13198895/SRR13198895_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR131/070/SRR13180570/SRR13180570_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR131/075/SRR13180575/SRR13180575_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR131/072/SRR13180572/SRR13180572_2.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR131/069/SRR13180569/SRR13180569_2.fastq.gzprimary200OKGenomicsState key laboratories of Agrobiotechnology, College of biological sciences, China Agricutural Universityhttps://www.ebi.ac.uk/ena/browser/view/PRJNA682022Homo sapiensChIPseq experiments identify that ASPSCR1-TFE3 defines active enhancers across the genome and co-distributes with VCP/p97. RNAseq after knock-down of ASPSCR1-TFE3 or VCP, inhibition of VCP, or overexpression of each in alveolar soft part sarcoma cell lines demonstrates their co-dependence. HiChIP defines chromatin conformations that surround ASPSCR1-TFE3 targets and are lost on VCP knock-down. Overall design: ASPS cell lines, tumors from ASPS mouse model and tumors from ASPS patients are used for ChIP-seq with antibodies against ASPSCR1, VCP, POLII and various histone modifications. RNAseq in ASPS cell lines after application of siRNA against control, ASPSCR1-TFE3, or VCP, or application of VCP inhibitor CB-5083. H3K27ac-HiChIP in the FU-UR-1 cell line at baseline and after 6 days of siRNA against VCP.xref:PubMed:38326311ENAHSPABP2, HEL-S-70, RGD1559642, d230, 2210017D18Rik, dCHIP, Ter94, dTAFII250, SCAR16, EfW1, ALS14, ter, 7.12, DmelCG2331, dmTAF[[II]]230, SDCCAG7., ASPCR1, DmelCG5203, RCCX1, dmTAF1, Taf230, Tfe-3, RCCP2, VCP ATPase, DmTER94, 2310040B03Rik, TAF250, VCP, Vcp, Taf200, TERA, dTAF[[II]]250, NY-CO-7, I, TFIID TAF250, cel, cell, Chip, ChIP, 15S Mg(2+)-ATPase p97 subunit, dvcp, CHIP, Taf1p, p97/VCP, 1190006K01Rik, IBMPFD, dTAF250, chip, l(2)03775, 22.26, aspcr1, dTERA, ter94, DmelCG3924, AW046544, dVCP, bHLHe33, UBOX1, TAF, 0610033N24Rik, transcription from bacterial-type RNA polymerase promoter, RCC17, PP1131, aspl, cdc48, dTAF[[II]]230, TAF[[II]]250, l(2)k04405, rcc17, p97, TAF200, CG5203, l(3)84Ab, CG2331, BG:DS00004.13, asps, TAFII-250, TAF250/230, l(2)04405, UBXN9, Cell, IBMPFD1, dTAF230, 3.6.4.6, dmTERA, TAFII250, Tera, TFEA, ASPS, Tcfe3, p230, ASPL, TAF[[II]]250/230, TFIID, BcDNA:GM02885, pTER94, BcDNA.GM02885, ASPC, ubxd9, Valosin-containing protein, Taf[[II]]250, TAF[[II]]230, dLdb, ubxn9, Ldb, LDB, HEL-220, Chromatin Immunoprecipitation, 3110001E05, CDC48, TAF[II]250, anon-WO2004063362.65, CG3924, CG17603, anon-WO2004063362.67, TAF[[II]], l(2)46Ch, DmelCG17603, TUG, dLDB/Chip, VCP/p97, l(2)46CFs, Taf250, p97|VCP, SR3-5, bacterial transcription, UBXD9, F830016E06Rik, Apple, TER ATPase, l(2)46CFf, TAF230, TAF1HSPABP2, HEL-S-70, RGD1559642, d230, 2210017D18Rik, dCHIP, Ter94, dTAFII250, SCAR16, EfW1, ALS14, ter, 7.12, DmelCG2331, dmTAF[[II]]230, SDCCAG7., ASPCR1, DmelCG5203, RCCX1, dmTAF1, Taf230, Tfe-3, RCCP2, VCP ATPase, DmTER94, 2310040B03Rik, TAF250, VCP, Vcp, Taf200, TERA, dTAF[[II]]250, NY-CO-7, I, TFIID TAF250, cel, cell, Chip, ChIP, 15S Mg(2+)-ATPase p97 subunit, dvcp, CHIP, Taf1p, p97/VCP, 1190006K01Rik, IBMPFD, dTAF250, chip, l(2)03775, 22.26, aspcr1, dTERA, ter94, DmelCG3924, AW046544, dVCP, bHLHe33, UBOX1, TAF, 0610033N24Rik, transcription from bacterial-type RNA polymerase promoter, RCC17, PP1131, aspl, cdc48, dTAF[[II]]230, TAF[[II]]250, l(2)k04405, rcc17, p97, TAF200, CG5203, l(3)84Ab, CG2331, BG:DS00004.13, asps, TAFII-250, TAF250/230, l(2)04405, UBXN9, Cell, IBMPFD1, dTAF230, 3.6.4.6, dmTERA, TAFII250, Tera, TFEA, ASPS, Tcfe3, p230, ASPL, TAF[[II]]250/230, TFIID, BcDNA:GM02885, pTER94, BcDNA.GM02885, ASPC, ubxd9, Valosin-containing protein, Taf[[II]]250, TAF[[II]]230, dLdb, ubxn9, Ldb, LDB, HEL-220, Chromatin Immunoprecipitation, 3110001E05, CDC48, TAF[II]250, anon-WO2004063362.65, CG3924, CG17603, anon-WO2004063362.67, TAF[[II]], l(2)46Ch, DmelCG17603, TUG, dLDB/Chip, VCP/p97, l(2)46CFs, Taf250, p97|VCP, SR3-5, bacterial transcription, UBXD9, F830016E06Rik, Apple, TER ATPase, l(2)46CFf, TAF230, TAF1falseASPSCR1-TFE3 reprograms transcription by organizing enhancers around hexameric VCP [Cell_lines_ChIP, ASPS1]ASPSCR1-TFE3 reprograms transcription by organizing enhancers around hexameric VCP [Cell_lines_ChIP, ASPS1]2025-09-242023-01-27PRJNA682022GSE162483960638326311